Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Worsening CKD was progressively associated with denosumab-induced hypocalcemia warranting emergency treatment. Denosumab use carries a higher risk for emergency hypocalcemia compared with ...

AUSTIN, Texas – One year of romosozumab (Evenity) followed by 1 year of denosumab (Prolia, Xgeva) was associated with improved bone mineral density (BMD) and lower fracture incidence compared with 2 ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

Among 1,032 Japanese patients on dialysis who started treatment for osteoporosis, denosumab use had a 45% lower risk for a composite of all fractures compared with oral bisphosphonates over 3 years ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and Osenvelt ...

The products are expected to be available in June 2025. Osenvelt is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid ...